AMGN — Amgen Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Amgen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	25,424	25,979	26,323	28,190	33,424
Cost of Revenue
Gross Profit	19,265	19,525	19,917	19,775	22,966
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	16,285	18,340	16,679	20,068	25,951
Operating Profit	9,139	7,639	9,644	8,122	7,473
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8,133	6,701	7,346	7,855	4,609
Provision for Income Taxes
Net Income After Taxes	7,264	5,893	6,552	6,717	4,090
Net Income Before Extraordinary Items
Net Income	7,264	5,893	6,552	6,717	4,090
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	7,264	5,893	6,552	6,717	4,090
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	12.3	12.9	12.9	12.6	11.1
Dividends per Share